Intermediate-term results with 1,019 Carbomedics aortic valves

Li, Huihua; Hahn, J; Urbanski, Paul P.; Torka, M.; Grunkemeier, Gary L.; Hacker, Robert J.

doi:10.1016/s0003-4975(00)02652-7

Cited by 16 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study with a follow-up up to 10 years, three patients required reoperation due to dehiscence of the aortic prosthesis, with a linearized incidence of 1.7% per 1000 patients-year, which is consistent with previous reports [2][3][4]. Therefore, performance of the CarboMedics 'Top-Hat' supraannular prosthesis is similar to the CarboMedics standard [13] and other second-generation bileaflet prostheses [14,15], but with evidence that the original design of the suture ring allows the use of larger sizes for the same diameter of the native annulus without increasing the risk of valve-related complications.…”

Section: Discussionsupporting

confidence: 90%

Performance at 10 years of the CarboMedics ‘Top-Hat’ valve. Postclamping time is a predictor of mortality

Bernal

Lorca

Prieto-Salceda

et al. 2006

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Performance at 10 years of the CarboMedics ‘Top-Hat’ valve. Postclamping time is a predictor of mortality

Bernal

Lorca

Prieto-Salceda

et al. 2006

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…Isolated insufficiency as cause of AVR is well presented in our cohort. Inferior early and long term survival has been shown for those patients, especially in younger age [9,10]. …”

Section: Discussionmentioning

confidence: 99%

Stentless aortic valve replacement in the young patient: long-term results

Christ

Grubitzsch

Claus

et al. 2013

J Cardiothorac Surg

View full text Add to dashboard Cite

BackgroundStentless aortic valve replacement (SAVR) became a common surgical procedure to treat aortic valve disease, as it offers larger orifice area and improved hemodynamics. The aim of our single-centre retrospective study was to assess long term results of first generation stentless aortic valves in young patients, where mechanical prostheses are considered first line therapy.MethodsFrom 1993 to 2001, 188 (149 male and 39 female) patients (≤60 years) underwent SAVR. Indications were in 63.3% stenosis or mixed lesions and in 36.7% isolated regurgitation. Mean age of patients at surgery was 53.1 ± 7.1 years. Associated procedures were performed in 60 patients (31.9%). Follow-up data were acquired through telephone interviews. Follow-up was 90.4% complete at a mean of 8.8 ± 4.7 years. Total follow-up was 1657.6 patient-years with a maximum of 17 years.ResultsOverall hospital mortality was 3.2% (2.5% for isolated SAVR). Overall actuarial survival-rate at 10/15 years and freedom from reoperation at 10/14 years were 73.0% ± 3.5%/ 55.8% ± 5.4% and 81.0% ± 3.4%/ 58.0% ± 7.5%, respectively. For isolated SAVR, actuarial survival at 10/15 years and freedom from reoperation at 10/14 years were 70.1% ± 4.4%/ 64.1% ± 4.8% and 83.1% ± 4.0%/ 52.9% ± 9.0%, respectively. Reoperation was performed in 42 patients (22.3%) due to structural valve deterioration and endocarditis. Age (≤50 years) and associated procedures did not significantly lower survival and freedom from reoperation, however, small prosthesis sizes (≤25 mm) did.ConclusionIn patients aged 60 and younger, SAVR provides reliable long-term results especially for larger aortic valves.

show abstract

“…10 The linearized rate of mechanical valve thrombosis is between 0.04 and 0.39% per patient-year. [11][12][13][14][15] Paravalvular leaks occur at a rate of 0.1-0.92% per patientyear, [15][16][17] and endocarditis at 0.1-0.53% per patient-year. [11][12][13] The differences found among the various reports might be caused by the differences in follow-up terms, patient populations, or prosthetic valve characteristics.…”

Section: Discussionmentioning

confidence: 99%

Twenty-Two Year Experience with the Omniscience Prosthetic Heart Valve

Misawa¹,

Taguchi²,

Aizawa³

et al. 2004

ASAIO Journal

View full text Add to dashboard Cite

This study was designed to evaluate the long-term clinical results of the Omniscience tilting disc valve. Omniscience valves were implanted in 51 patients (mean age, 50 +/- 10 years); 18 had aortic valve, 24 had mitral valve, and 9 had both aortic and mitral valve replacements. Oral warfarin potassium and dipyridamole were prescribed as our anticoagulant therapy. Preoperatively, 42 patients were in New York Heart Association class III or IV, and 23 of 25 surviving patients were in class I or II after operation. There were 2 (3.9%) early deaths and 23 late deaths (3.5 +/- 0.7% per patient-year). Cardiac related mortality including congestive heart failure, sudden death, and thromboembolism, and hemorrhagic complications were seen in 16 patients. Overall survival at 10, 15, and 20 years was 77 +/- 6%, 62 +/- 7%, and 46 +/- 7%, respectively. Thromboembolic complications were seen in 5 patients, for a rate of 0.8 +/- 0.3% per patient-year; similarly, hemorrhagic complications were also seen in 5 patients. Nonstructural prosthetic valve dysfunction was seen in 4 patients, for a rate of 0.6 +/- 0.3% per patient-year, and sudden death was seen in 2, a rate of 0.3 +/- 0.2% per patient-year. The Omniscience prosthesis demonstrated excellent postoperative clinical status with low rates of valve related complications.

show abstract

Intermediate-term results with 1,019 Carbomedics aortic valves

Cited by 16 publications

References 18 publications

Performance at 10 years of the CarboMedics ‘Top-Hat’ valve. Postclamping time is a predictor of mortality

Performance at 10 years of the CarboMedics ‘Top-Hat’ valve. Postclamping time is a predictor of mortality

Stentless aortic valve replacement in the young patient: long-term results

Twenty-Two Year Experience with the Omniscience Prosthetic Heart Valve

Contact Info

Product

Resources

About